Bionovis was born in 2012, from the union between the renowned Brazilian laboratories Aché, EMS, Hypera Pharma and União Química. As a pharmaceutical biotechnology joint venture, we have become leaders and pioneers in the national production of highly complex biological medicines and biosimilars.
We have established collaborations with prominent global players in the sector and prominent public laboratories in Brazil. Through these strategic alliances, we acquire advanced technologies for the manufacture of innovative biopharmaceuticals, biosimilars and biobetters.
Today, some of our biopharmaceuticals are in an advanced stage of technology transfer and already serve the Ministry of Health, providing access to high standard therapies in the entire Brazilian territory. This movement reinforces our commitment and position in strengthening the pharmaceutical biotechnology sector in Brazil.
The pharmaceutical biotechnology joint venture is formed by the union of laboratories Aché, EMS, Hypera Pharma and União Química.
Signed with Janssen-Cilag, owner of the biopharmaceutical Infliximab
For the production of the biological Interferon beta-1a.
Our Biotech is starting to come to life
Pilot Plant, Quality Laboratory and logistics operations
For technology transfer of biosimilar etanercept, supplied to the SUS.
For biosimilar rituximab technology transfer.
For technology transfer of biosimilar trastuzumab.
For golimumab technology transfer.
Start of operations of the industrial plant for the production of biopharmaceuticals.
For technology transfer of biosimilar adalimumab.
We started the development of Bionovis BNV-007 in our Biotech.
For commercialization of pegfilgrastim.
We started the development of Bionovis BNV-008 in our Biotech.
Expansion of our Biotech suite B.
For commercialization of bevacizumab.
We believe that the search for success and efficiency will only be valid if business conduct is guided by solid principles of integrity, respect, loyalty and justice.
We work with the purpose of expanding the Brazilian population’s access to innovative medicines, always inline with the most rigorous scientific, technical and ethical standards.
Bionovis is a pioneer in the production and commercialization of biological and biosimilar medicines.
Our search for scientific innovations and highly complex medicines aims to build a healthier Brazil and world for everyone.
© 2025 Bionovis. Companhia Brasileira de Biotecnologia Farmacêutica.
